PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?-Reference-Cited by-同舟云学术

PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

Published:2015-07-07 Issue:1 Volume:163 Page:64-65
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Cainzos-Achirica Miguel¹,Martin Seth S.¹,Cornell John E.¹,Mulrow Cynthia D.¹,Guallar Eliseo¹

Affiliation:

1. From Johns Hopkins Medical Institutions, Baltimore, Maryland; University of Texas Health Science Center, San Antonio, Texas; American College of Physicians, Philadelphia, Pennsylvania, and Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuevos fármacos hipolipemiantes;FMC - Formación Médica Continuada en Atención Primaria;2023-12

2. Hypolipidemic drugs inhibiting the proprotein convertase of subtilisin/kexin type 9 (PCSK9): monoclonal antibodies, antisense oligonucleotides, small interfering ribonucleic acids;Reviews on Clinical Pharmacology and Drug Therapy;2021-05-21

3. Dianas terapéuticas en el tratamiento de las dislipemias: de las estatinas a los inhibidores de PCSK9. Necesidades no cubiertas;Clínica e Investigación en Arteriosclerosis;2021-05

4. New groups of hypolipidemic medications based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1;Clinical Medicine (Russian Journal);2021-04-18

5. New groups of hypolipidemic drugs based on inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). Part 1;Science and Innovations in Medicine;2021-03-29